Detail akcie Monopar Therape Rg online

Business Summary: Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Monopar Therapeutics Inc revenues was not reported. Net loss increased 83% to $8.5M. Higher net loss reflects Research and development - Balancing val increase of 68% to $4.3M (expense), Stock-based Compensation in SGA increase from $326K to $2M (expense), Stock-based Compensation in R&D increase from $537K to $1.7M (expense).